Along with researchers in the Faculty of Health Sciences and the Faculty of Science, Western projects received a total of $17 ...

Can we fix errors in our genetic blueprint that lead to debilitating disorders like Huntington's disease?How can we better support newcomers to Canada ...

The Madison Re-Prom is returning to the Monona Terrace this February for its 13th year. The annual gala brings grown ups back ...

New research suggests that electrical spinal cord stimulation could improve muscle function for patients who have spinal ...

LEXINGTON, Mass. - uniQure N.V. (NASDAQ: NASDAQ:QURE), a gene therapy company with a market capitalization of $767 million, ...

In a small human trial in SMA patients neurostimulation sessions improved motoneuron function, reduced fatigue, and improved leg muscle strength and walking.

Leerink Partners analyst Joseph Schwartz has reiterated their bullish stance on QURE stock, giving a Buy rating on January 27.Maximize Your ...

Feb. 6, 2025 — A research team has discovered that the two key pathological hallmarks of Alzheimer's -- tau protein and beta-amyloid -- affect brain circuits in distinct yet synergistic ways ...

Researchers are enhancing the best features of AAV capsids and overcoming their limitations to accelerate gene-based therapies.

Genetics researchers studied eFAD families to discover the ... number than more visible neurodegenerative diseases such as ALS (Lou Gehrig disease) and Huntington disease. When put to AD researchers, ...

WVE-007 is a novel, long-acting GalNAc-siRNA targeting INHBE mRNA – a genetically validated target that provides a new approach for healthy, ...

uniQure says it has reached an agreement with the FDA on a pathway to accelerated approval for its Huntington's disease gene therapy based on a phase 1/2 trial. The announcement led to a doubling ...